Pharmacists hope a new Congress will roll back reimbursement cutbacks that were originally slated
With the Democrats taking over Congress in 2007, the business outlook for pharmacists is looking up-at least, that's what pharmacy leaders are hoping.
Community pharmacists are pinning their hopes on the 110th Congress to roll back reduced reimbursement for generic drugs under Medicaid. A big worry is the advent of average manufacturers price (AMP) to replace average wholesale price as the new basis for Medicaid reimbursement next month. At press time, final guidelines on AMP have not been issued yet.
Whether cutbacks in Medicaid payment can be stanched is unknown. What is known is that pharmacists will be facing these new challenges in 2007:
To gauge how pharmacists are preparing for 2007, Drug Topics conducted an on-line survey of independents, chain executives, and hospital pharmacists. Until this year, our annual business outlook survey had always been done as a written questionnaire mailed to readers. This year, however, we switched to an on-line format. Responses were received from 92 independents, 85 hospital R.Ph.s, and 18 chain executives. To boost responses on the chain side, individual executives were also contacted by phone.
Here's how pharmacists are handicapping 2007.
Examining Impact of COVID-19 Diagnosis Timing on AF Progression | AHA 2024
November 21st 2024“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.